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CD2-associated protein (CD2AP) is a scaffold molecule that
plays a critical role in the maintenance of the kidney filtration
barrier. Little, however, is understood about its mechanism of
function. We used mass spectrometry to identify CD2AP-interacting proteins. Many of the proteins that we identified suggest
a role for CD2AP in endocytosis and actin regulation. To
address the role of CD2AP in regulation of the actin cytoskeleton, we focused on characterizing the interaction of CD2AP
with actin-capping protein CP. We identified a novel binding
motif LXHXTXXRPK(X)6P present in CD2AP that is also found
in its homolog Cin85 and other capping protein-associated proteins such as CARMIL and CKIP-1. CD2AP inhibits the function
of capping protein in vitro. Therefore, our results support a role
of CD2AP in the regulation of the actin cytoskeleton.

CD2-associated protein (CD2AP)2 is a 70-kDa protein that
was originally cloned as a protein that interacts with the cytoplasmic tail of CD2, a T lymphocyte and natural killer cell transmembrane protein (1). It is composed of three Src homology 3
(SH3) domains at the NH2 terminus followed by proline-rich
sequences and a coiled-coil domain at the extreme COOH terminus. It is expressed in all tissues except brain. Interestingly,
CD2AP-deficient animals die of renal failure ⬃6 weeks of age
(2). In the kidney, CD2AP is highly expressed in the glomerular
epithelial cell, and it is implicated to play a role in a specialized
cell junction known as a slit diaphragm (3).
A homolog of CD2AP, Cin85, was cloned as an interacting
protein with the E3 ubiquitin ligase c-cbl (4) and as an inhibitor
of phosphatidylinositol 3-kinase (5). Recently, several endocytic and actin-associated molecules have been reported to
interact with CD2AP and Cin85. Some proteins have been
demonstrated to interact with both CD2AP and Cin85, whereas
others have only been shown to bind one or the other. CD2AP
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has been shown to play a role in vesicular trafficking because of
interactions with c-cbl and an active form of Rab4 (6). Cin85 has
also been shown to bind to molecules involved in endocytosis,
such as endophilin, synaptojanin 2B1, and SHIP-1 and the
clathrin scaffold HIP1R (7, 8). Both CD2AP and Cin85 contain
a motif, FXDXF, that mediates interactions with the ␣-appendage of clathrin adaptor protein 2 (9). Interactions of CD2AP and
Cin85 with the phosphatidylinositol bisphosphate-dependent
GTPase for ARF1 and ARF5, known as ASAP1, as well as cortactin- and actin-capping protein suggest additional roles in the
regulation of the actin cytoskeleton (7, 10 –12).
To further elucidate the molecular mechanism of CD2AP
function, we performed mass spectrometry to identify interacting proteins. We identified novel and previously known interacting proteins such as actin-capping protein CP (11).
Over the last decade, there has been much progress in our
understanding of how the actin cytoskeleton is regulated. Critical is the polymerization of monomeric G-actin to forming an
asymmetric actin filament with a barbed and a pointed end. The
barbed end is favored for polymerization. The Arp2/3 complex
and formins can nucleate actin polymerization by creating free
barbed ends, whereas gelsolin and actin-capping protein CP
cap the barbed end (13, 14).
CP is a ubiquitously expressed heterodimer of ␣ and ␤ subunits (15). It is enriched in lamellipodia, and it plays an important role in cell motility (13). CP binds to the barbed end of the
actin filament and prevents the addition and removal of actin
subunits (16). By limiting the growth of pre-existing actin filaments, CP enhances new actin filament branching by the
Arp2/3 complex (17). Recently, several proteins (CARMIL,
CKIP-1, and V-1) have been demonstrated to bind and inhibit
CP activity (18 –20).
To understand the role of CD2AP in actin cytoskeleton
dynamics, we decided to focus on characterizing the interaction
of CD2AP with CP. Even though this interaction was previously
reported (11), the mode of binding and the effect of CD2AP on
the activity of CP are not known. In this report, we confirmed
the binding of CD2AP with CP, and we mapped the interaction.
This allowed us to identify a novel capping protein binding
motif recognized by CP that is present in CD2AP, Cin85,
CKIP-1, and CARMIL.

EXPERIMENTAL PROCEDURES
Co-immunoprecipitation—Co-immunoprecipitations were
performed as described previously (21). Briefly, HEK293T cells
VOLUME 281 • NUMBER 28 • JULY 14, 2006
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were transiently transfected with SuperFect (Qiagen, Valencia,
CA). After incubation for 24 h, the cells were washed twice with
phosphate-buffered saline and lysed in 1% Triton X-100 lysis
buffer (20 mM Tris-HCl, pH 7.5, 25 mM NaF, 12.5 mM Na4P2O7,
0.1 mM EDTA, 50 mM NaCl, 2 mM Na3VO4, and protease inhibitors). After centrifugation (15,000 ⫻ g, 15 min, 4 °C) to remove
cellular debris, the supernatant was subjected to an ultracentrifugation (100,000 ⫻ g) for 30 min. Equal amounts of total
protein were incubated for 1 h at 4 °C with anti-FLAG M2-agarose (Sigma). The beads were washed extensively with lysis
buffer.
Preparation of Samples for Mass Spectrometry—Immunoprecipitates were separated on SDS-polyacrylamide gels and
stained with GelCode Blue Colloidal Coomassie reagent (MJS
BioLynx Inc., Brockville, ON, Canada) as previously described
(22). Silver staining of gels was performed as described by
Shevchenko et al. (23). Individual bands were excised from the
gel with a scalpel and placed into a single well of a 96-well
microtitre plate (Genomic Solutions, Ann Arbor, MI). Reduction, alkylation, and “in-gel” tryptic digestion of samples was
performed with a Genomic Solutions ProGest digestion robot
as previously described (24). Tryptic peptides were then
extracted from the gel for analysis by mass spectrometry.
Liquid Chromatography-Tandem Mass Spectrometry—
Tryptic peptides were analyzed by liquid chromatography-tandem mass spectrometry with a HP 1100 HPLC system (Palo
Alto, CA) connected to an LCQ-Deca mass spectrometer
(Thermo Electron, San Jose, CA) as previously described (22).
Data were analyzed with both the Mascot (4) and Sonar ms/ms
(Genomic Solutions) search engines.
Plasmids—Glutathione S-transferase (GST) fusion proteins
were made using the PGEX-KG vector (25). A DNA fragment
encoding the COOH-terminal CD2AP (residues 324 – 636) was
cloned in-frame into vector cut with BamHI and EcoRI.
Sequences encoding a COOH-terminal fragment of CD2AP
lacking the proline-rich sequence CT⌬PR (residues 424 – 636)
was amplified by PCR using Pfu polymerase (Stratagene) and
cloned in-frame into the NcoI and SalI sites of PGEX-KG. The
COOH-terminal construct lacking the coiled-coil domain
CT⌬CC (residues 424 –588) was generated by deletion
mutagenesis of residues encoding 589 – 636. Constructs encoding residues 424 –528 and 474 –588 were generated by deletion
mutagenesis of CT⌬PR. The construct encoding residues 474 –
528 was generated by deletion mutagenesis using the construct
encoding residues 478 –592 as the starting point. The construct
encoding residues 474 –528 was used to generate constructs
with residues 474 –513, 474 –598, 490 –528, and 506 –528 by
deletion mutagenesis. Point mutations in CT⌬PR (L486A,
H488A, T490A, N492A, R493A, K495A, R500A, and P502A)
were generated by site-directed mutagenesis by PCR.
Proteins—GST fusion proteins were expressed in Escherichia
coli and affinity-purified using standard procedures using glutathione-agarose (Sigma). Chicken-capping protein CP ␣1 and ␤1 subunits were co-expressed in E. coli using the pET-3d vector and
purified as described previously (16). The CP deletion mutants
␣1⌬␤1 (␣1 COOH-terminal 28-amino-acid deletion mutant),
␣1␤1⌬ (␤1 COOH-terminal 34-amino-acid deletion mutant), and
JULY 14, 2006 • VOLUME 281 • NUMBER 28

␣1⌬␤1⌬ (double COOH-terminal region deletion mutant) were
purified as described in Ref. 16.
Confirmatory sequencing of all constructs was done using
Big-Dye 3.1 (Applied Biosystems). Purified proteins were analyzed by SDS-PAGE and Coomassie staining. Protein concentrations were estimated using the BCA protein assay (Pierce)
and by absorbance measurement at 280-nm wavelength.
BIAcore Analysis—The experiments were carried out using a
BIAcore 2000 at 25 and 30 °C for both binding detection and
affinity measurements. Goat anti-GST antibody (BIAcore,
Uppsala, Sweden) was cross-linked to CM5 chips using amine
coupling (BIAcore). CD2AP constructs fused to GST were then
loaded onto chips containing the immobilized anti-GST antibody in a buffer containing 10 mM Hepes, pH 7.4, 150 mM NaCl,
4 mM EDTA, and 0.005% Tween 20. CP was injected at various
concentrations at a flow rate of 25 l/min.
To measure the affinity by Scatchard analysis, CP was
injected at various concentrations, and the equilibrium binding
was obtained and plotted. The binding kinetic rate constants
were obtained by using BIAevaluation version 3.1 software
(BIAcore). The koff rate was measured by co-injecting soluble
CD2AP during the dissociation phase of the reaction.
To compare the binding of various mutated constructs,
similar amounts of GST-CD2AP constructs were captured
on the chip. Because the magnitude of the response is related
to the mass of the analyte, we corrected for differences in the
molecular weights of each construct and variances in the
amount immobilized on the chip using the equation
RUmax ⫽ RUligand ⫻ (molecular weight of analyte/molecular weight of ligand). This allowed us to calculate a relative
RUmax for each construct. The percent binding of the
mutated construct in comparison to the wild-type construct
was then computed by comparing the actual RU of the bound
CP at steady state (Req) to the calculated Rmax.
Peptides—The 22-mer peptides used for the competition
assay were synthesized by standard Fmoc chemistry using a
multiple peptide synthesizer (Symphony/Multiplex; Protein
Technologies, Tucson, AZ). All peptides were purified by
HPLC, and their sequences were verified by mass spectrometry.
The sequences of the peptides used were: CARMIL, RRLEHFTKLRPKRNKKQQTQA; CKIP-1, SYLAHPTRDRAKIQHSRRPPTR; CD2AP, ENLLHLTANRPKMPGRRLPGRF; and
CD2AP (R493A), ENLLHLTANAPKMPGRRLPGRF (the bold
letter indicates the mutation).
Spectrin F-actin-seeded Actin Polymerization Assay—Proteins and spectrin F-actin seeds were prepared and assayed as
described in Ref. 16. Actin was used at a final concentration of
1.5 M (3% pyrene-labeled) in 1⫻ polymerization buffer (10 mM
Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 0.2 mM ATP, 0.5 mM
dithiothreitol, 0.2 mM CaCl2, and 1 mM EGTA). Ca2⫹-G-actin
was primed for 90 s prior to the initiation of polymerization by
adding a 1⁄10 volume of 10 mM EGTA, 1 mM MgCl2 to exchange
Ca2⫹ to Mg2⫹. A 1⁄20 volume of 20⫻ polymerization buffer (200
mM Tris-HCl, pH 7.5, 1 M KCl, 20 mM MgCl2, and 20 mM
EGTA) was then added to initiate polymerization. CP, GSTCD2AP (CT⌬PR), and GST-CD2AP-(474 –513) were in 10 mM
Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 0.5 mM dithiothreitol, and 1 mM EGTA. The CP and CP-CD2AP mixtures were
JOURNAL OF BIOLOGICAL CHEMISTRY
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added to the actin mixture immediately after priming, followed
by the addition of 20⫻ polymerization buffer, followed by 10 l
of spectrin F-actin seed. The solution was mixed and placed in
the fluorometer with a total dead time of 20 s. The solution was
then recovered and incubated overnight at 25 °C to reach equilibrium to allow for measurements at steady state. The steadystate binding data were analyzed using PRISM4 software.
Actin Uncapping Assay—The uncapping assay was a modification of the actin polymerization assay using 1 M actin (5%
pyrene-labeled) and 2 nM CP. It was performed essentially as
described in Ref. 26. Uncapping activity is defined as the rate of
polymerization, calculated from the slope of the pyrene fluorescence versus time, following the addition of CARMIL or
CD2AP-(474 –513).

RESULTS
Identification of CD2AP-associated Protein by Mass Spectrometry—To identify CD2AP-interacting proteins, an epitopetagged version of CD2AP was overexpressed in HEK293 cells
and immunoprecipitated. The co-precipitated proteins were
analyzed by SDS-PAGE and silver staining. The identification
of protein bands was performed using mass spectrometry. In
addition to CD2AP, several previously described CD2AP-interacting proteins were identified, such as actin (27), cortactin
(12), and actin-capping protein CP (11). Novel interacting partners were also identified. These included Cin85 (4, 5), tensin
(28), clathrin adaptor protein 2, two Rho and Rac GTPase-activating proteins centaurin ␦2 (29) and SH3BP1 (30), synaptojanin 2 (31), glial fibrillary acidic protein (GFAP), RNA-binding
protein 10, heat shock protein (HSP70), and breast cancer type
1-susceptible protein (BRCA1) (32).
The identification of multiple proteins involved in actin
cytoskeletal regulation suggested that CD2AP participates in
the regulation of the actin cytoskeleton. Because CP plays an
important role in the assembly of various actin structures, we
hypothesized that CD2AP might regulate the activity of CP. We
therefore focused on characterizing the interaction of CP with
CD2AP in more detail.
Mapping the Interaction Domain—Previously, an interaction
of CP with the COOH-terminal half of CMS (Cas ligand with
multiple SH3 domains), the human ortholog of CD2AP, was
reported (11). To confirm this, we generated a GST fusion protein containing residues 324 – 636 of CD2AP and tested it for
interaction with purified CP using surface plasmon resonance
(SPR). CD2AP was immobilized on the chip, and CP was used as
the analyte. As predicted, the fragment encoding the COOHterminal half of CD2AP interacted with CP (Fig. 1B). Scatchard
analysis showed that this fragment bound to CP with a dissociation constant (KD) of 2.4 nM. Real-time measurements
revealed binding kinetics of kon ⫽ 9.6 ⫻ 105 M⫺1 s⫺1 and
koff ⫽ 2.3 ⫻ 10⫺3 s⫺1 (Fig. 1C).
The COOH-terminal half of CD2AP is notable for prolinerich sequences followed by a predicted coiled-coil domain near
the extreme COOH terminus (1). We first tested the requirement of the coiled-coil domain for binding to CP by generating
a construct lacking the coiled-coil domain CT⌬CC (residues
324 –588). Using SPR, we found that this construct still bound

19198 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 1. CP requires neither the proline-rich sequence nor the coiledcoil domain of CD2AP for binding. A, schematic representation of the
COOH-terminal domains of CD2AP. B, CD2AP lacking the proline-rich
sequence and the coil-coil domain bind CP. Constructs encoding fragments
of CD2AP lacking the proline-rich sequence (CT⌬PR) or lacking the coiled-coil
domain (CT⌬CC) were generated by PCR and expressed in bacteria. The interaction between CD2AP constructs and CP was measured using surface plasmon resonance. The CD2AP constructs were immobilized on the chip using a
GST capturing kit protocol. GST alone in a separate flow cell was used as a
negative control (CT ) test for an interaction, and CP (50 nM) was injected onto
the chip. The binding of the control was set to 100%. Each analysis was corrected for differences in the molecular weight and for variances in initial
immobilization as described under “Experimental Procedures.” C, CP binds to
CD2AP with a high affinity. Increasing amounts of CP (0.1, 0.3, 0.5, 1.5, 4, 12,
and 36 nM) were injected over immobilized CT⌬PR to measure the binding
affinity. BIAevaluation analysis was carried out to determine the binding rate
constants (kon ⫽ 9.6 ⫻ 105 M⫺1 s⫺1, koff ⫽ 2.3 ⫻ 10⫺3 s⫺1). The binding affinity was calculated to be 2.4 nM using Scatchard plot analysis. RU, resonance
units.

to CP. Therefore, the coiled-coil domain is not required for
binding (Fig. 1B).
Next, we tested whether the proline-rich sequences of
CD2AP were required for binding. A construct, CT⌬PR (residues 428 – 636), lacking the proline-rich sequences between
324 and 428, was generated and tested for its ability to bind CP
by SPR. This construct also retained binding to CP, suggesting
that the proline-rich sequences were not required for binding
(Fig. 1B). Therefore, we deduced that the region of CD2AP
between the proline-rich sequences and the coiled-coil domain
(residues 424 –588) contains the CP binding region.
To define the interaction site further, we generated additional truncation mutants. Because this region has no predicted
secondary structure, we generated constructs eliminating
either 60 residues from the COOH terminus (residues 424 –
VOLUME 281 • NUMBER 28 • JULY 14, 2006

Identifying a Novel Actin-capping Protein Binding Motif

FIGURE 2. Defining minimal CD2AP and CP binding domains. A, various
truncation mutants of CD2AP were tested for CP binding using SPR. Each
construct was generated by PCR mutagenesis and expressed as fusion proteins in bacteria. Purified proteins were immobilized on the chip, and CP binding was assessed as described in the legend to Fig. 1. B, the region 474 –513 is
sufficient to bind CP with high affinity. A fragment containing residues 474 –
513 was immobilized on the BIAcore chip. A range of concentrations of CP
(0.1, 0.3, 1, 3, 9, 30, and 100 nM) was injected onto the chip. Scatchard analysis
generated an affinity of 5.6 nM. BIAevaluation analysis generated binding rate
constants of kon ⫽ 4.67 ⫻ 105 M⫺1 s⫺1 and koff ⫽ 2.6 ⫻ 10⫺3 s⫺1. RU, resonance units. C, various truncation mutants of CP were tested for CD2AP binding. CT⌬PR was immobilized to the chip, and 50 nM ␣ COOH-terminal region,
␤ COOH-terminal region, and ␣␤ double COOH-terminal regions deletion
mutants of CP were tested for CD2AP binding using SPR.

528) or 50 residues from the NH2-terminal end (residues 474 –
588). Both constructs retained binding to CP (Fig. 2A), narrowing the binding region to residues 474 –528.
The region 474 –528 was sufficient for binding, because a
construct encoding just these residues was able to bind to CP
measured by SPR (Fig. 2A). We narrowed the binding site further by generating additional constructs, deleting residues from
both the NH2 and COOH termini. Although the construct
JULY 14, 2006 • VOLUME 281 • NUMBER 28

encoding residues 474 –513 retained binding to CP, the construct encoding residues 474 – 498 had impaired binding. Thus,
residues between 474 and 513 were sufficient for CP binding
(Fig. 2A).
We measured the binding affinity of this minimal binding
region of CD2AP (residues 474 –513) with CP. Scatchard analysis showed that CD2AP bound to CP with a KD of 5.6 nM, and
real-time measurements showed binding kinetics of
kon ⫽ 4.7 ⫻ 105 M⫺1 s⫺1 and koff ⫽ 2.6 ⫻ 10⫺3 s⫺1 (Fig. 2B).
Because this affinity is similar to the one measured for the interaction of the entire COOH-terminal half of CD2AP with CP,
this region was sufficient to account for CP binding.
CP is a heterodimer of ␣ and ␤ subunits. The COOH termini
of both subunits are known to be important for its actin-capping activity (16). To test the importance of these regions for
the interaction with CD2AP, CP constructs lacking the ␣
COOH-terminal region, the ␤ COOH-terminal region, or both
were tested for binding to CT⌬PR. CP lacking the ␣ COOHterminal region or both the ␣ and ␤ COOH termini regions did
not interact with CD2AP, whereas CP lacking just the ␤
COOH-terminal region had an intermediate binding ability
(Fig. 2C). Hence, CD2AP requires both ␣ and ␤ COOH termini
regions of CP for efficient binding. These results predicted that
CD2AP should inhibit capping activity of CP.
Identification of CP Binding Motif—Recently, the binding
regions for two CP-binding proteins, CKIP and CARMIL, were
reported (18, 20). To determine whether these binding sites had
similarities to residues 474 –513 of CD2AP, we performed a
CLUSTAL analysis. The sequence alignment illustrated in Fig.
3A shows that all three proteins share a similar pattern of residues, LXHXTXXRPK(X)6P (where X is any amino acid) suggesting that this may be the CP binding motif.
To determine whether the residues in this motif are important for CP binding, we mutated each of the conserved residues
to alanine in the CT⌬PR construct (residues 428 – 636). Each
mutant was tested for CP binding using SPR (Fig. 3B). Mutation
of the conserved leucine, arginine, and proline residues (Lue486, Arg-493, Pro-502) completely ablated binding, whereas
mutations of the other conserved residues significantly
impaired but did not completely ablate binding. Importantly,
mutations of two non-conserved residues in CD2AP, N492 and
R500, did not affect binding of CP to CD2AP. Therefore, we
concluded that the LXHXTXXRPK(X)6P motif in CD2AP is
necessary for binding.
To verify that the LXHXTXXRPK(X)6P motif found in all
three proteins (CD2AP, CARMIL, and CKIP-1) is the binding
site, we tested 22-mer peptides corresponding to this motif
from CKIP-1 and CARMIL in a competition assay against the
CD2AP protein. The ability of the CKIP-1 and CARMIL peptides to inhibit CD2AP binding to CP (Fig. 3C) confirmed that
all three of these proteins use this motif to bind to CP, and
therefore this motif is sufficient for binding.
Inhibition of CP Activity by CD2AP—Because both the actincapping activity and CD2AP binding required the COOH-terminal regions of CP, we were interested to test whether CD2AP
binding could affect CP-capping activity. This was tested using
a pyrene-actin polymerization assay for barbed end growth
in vitro as described under “Experimental Procedures.” The
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. Identification of CP binding motif. A, CLUSTAL analysis of CD2AP, Cin85, CKIP-1, and mCARMIL. The
residues conserved within these proteins are highlighted in bold. The proposed motif is shown underneath. The
one-letter amino acid representation is used. X represents any amino acid. B, identification of critical binding
site residues. Each of the conserved residues defined in A was mutated to alanine using site-directed mutagenesis. In addition, two of the non-conserved residues (Arg-500 and Asn-492) were mutated as a negative control.
Each mutated construct was expressed in bacteria, purified, and tested for binding to CP. Each analysis was
corrected for differences in the molecular weight and for variances in initial immobilization as described under
“Experimental Procedures.” WT, wild type. C, synthetic peptides derived from CD2AP, CKIP-1, and CARMIL
compete for binding to CP. Peptides corresponding to the putative CP binding site in CD2AP, CKIP-1, and
CARMIL were synthesized using standard Fmoc chemistry. The sequence of the 22-mer peptides is given under
“Experimental Procedures.” SPR was used to measure the ability of peptides to inhibit the binding of CP to
CD2AP. Briefly, 50 nM CP was incubated with 1 M peptide and injected. As a negative control, a peptide
derived from CD2AP with Arg-493 changed to alanine was also tested.

polymerization of pyrene-actin as assessed by its fluorescence
was measured over time. The addition of up to 500 nM CT⌬PR
alone to the reaction mixture did not have any effect on actin
polymerization, and as expected, the addition of CP inhibited
barbed end growth. Addition of CT⌬PR to CP inhibited the
activity of CP in a concentration-dependent manner (Fig. 4A).
A similar effect was observed with the addition of the minimal
binding domain (residues 474 –513) (data not shown). The
inhibitory effect of CD2AP on the activity of CP was saturated
when the CT⌬PR concentration reached ⬃500 nM (Fig. 4A).
Because this is much higher than the KD of CP for CD2AP, we
suggest that the inhibition of CP by CD2AP is not complete.

19200 JOURNAL OF BIOLOGICAL CHEMISTRY

The partial inhibitory effect of
CD2AP on CP actin-capping activity was confirmed using a steadystate polymerization assay. In this
experiment, the effect of CD2AP
was allowed to go to equilibrium by
allowing the reaction to go to completion; actin fluorescence was
measured after 18 h. Using PRISM4
software, the affinity of CD2AP for
CP was found to be similar to that
measured by SPR (Fig. 4B). In addition, because the activity of CP was
not completely inhibited, this suggests that the CD2AP䡠CP complex
still retains some filament-capping
activity. As shown in Fig. 4B, after the
complex had reached equilibrium,
full actin polymerization had not been
achieved, suggesting that the
CD2AP䡠CP complex retains a low but
detectable affinity for the barbed end.
Taken together, the results show
that CD2AP partially inhibits the
capping activity of CP and that the
CP䡠CD2AP complex has the ability
to cap the barbed end but at a much
slower rate.
The ability of CD2AP to uncap
actin filaments was also tested (Fig.
4C). 500 nM CD2AP-(474 –513) was
added to actin polymerization reactions containing CP at a time when
most of the barbed ends were already
capped. The addition of CD2AP(474 –513) resulted in increased actin
polymerization, consistent with the
dissociation of CP from F-actin.

DISCUSSION

In this report, we present data
supporting the role of CD2AP as a
regulator of the actin cytoskeleton.
In a proteomic screen, we identified
several actin regulatory proteins
associated with CD2AP, including
actin capping protein, cortactin,
and synaptojanin. By mapping its interaction with CP, we identified a novel motif in CD2AP that is also found in Cin85,
CKIP-1, and CARMIL that mediates binding to CP. Because
CD2AP inhibits the activity of CP, the interaction between CP
and CD2AP appears to be functionally relevant.
In the proteomic screen, we identified known CD2AP-interacting proteins, including capping protein and cortactin (11,
12). Synaptojanin is reported to bind to Cin85 but has not yet
been reported to bind to CD2AP (7). We also identified new
CD2AP-binding proteins. Although the clathrin adaptor protein 2 was implicated as a CD2AP-interacting protein because
of the presence of the FXDXF binding motif (9), this is the first
VOLUME 281 • NUMBER 28 • JULY 14, 2006

Identifying a Novel Actin-capping Protein Binding Motif

FIGURE 4. CD2AP inhibits CP and also exhibits uncapping activity.
A, CD2AP inhibits CP activity. Actin polymerization was measured using a
fluorescence-based pyrene-actin assay. Spectrin actin seeds were used to
initiate actin polymerization. CP (4 nM) was added by itself or after preincubation with CT⌬PR at the indicated concentrations. B, the binding
affinity of CP and CD2AP was determined from steady-state F-actin polymerization measurements. To a solution containing 1.5 M actin and spectrin F-actin seeds (filled diamond), 5 nM CP with or without increasing
amounts of CD2AP-(474 –513) (5, 15, 50, and 150 nM) were added. Samples
were incubated overnight to reach equilibrium before fluorescence measurement. C, CD2AP promotes the dissociation of CP from actin filaments.
Actin polymerization was initiated as described for a and b with spectrin
F-actin seed and the addition of CP (2 nM). After 400 s, 500 nM CD2AP(474 –513) or 40 nM CARMIL was added. An equal volume of buffer alone
was also added as a negative control. Actin polymerization was measured
using a fluorometer.

demonstration that CD2AP can, in fact, bind to it. Other novel
interactions include centaurin ␦2 and SH3BP1, which are
GTPase-activating proteins for the Rho and Rac GTPases,
respectively (29, 30). We also identified tensin, a focal adhesion
protein with multiple actin binding domains, which is a known
inhibitor of actin polymerization (28). On the other hand, we
did not find other reported CD2AP-binding proteins, such as
Fyn, Src, Yes, or the p85 regulatory subunit of phosphatidylinositol 3-kinase (33). This might be because these proteins have
a transient or low affinity interaction with CD2AP. It is also
possible that the conditions we used in our screen did not favor
their binding to CD2AP. We also identified other proteins of
unknown significance, such as RNA-binding protein 10, glial
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fibrillary acidic protein, and the breast and ovarian cancer susceptibility protein BRCA1 (32). Further work will be needed to
determine the significance of these interactions.
To better define the CD2AP/CP interaction, we mapped the
minimal binding region of CD2AP to amino acids 474 –513.
This domain does not have any predicted secondary structure
and is located between the proline-rich sequences and coiledcoil domain at the COOH terminus. Using a CLUSTAL analysis
to compare this sequence to the sequences of two other known
CP-binding proteins, CKIP-1 and CARMIL, we identified the
novel motif LXHXTXXRPK(X)6P. This motif is also found in
Cin85. Since the original submission of the manuscript of this
article, Urono et al. (34) report that a conserved sequence similar to the motif we describe is present in all known forms of
CARMIL.
Mutations of all of the conserved residues showed that they
are important for binding, with Leu-486, Arg-493, and Pro-502
being the most critical residues. Consistent with our findings,
mutation of the analogous arginine in CARMIL was recently
shown to be important for CP binding (20). Pro-494 of CD2AP
is conserved in Cin85 and CARMIL; however, it is alanine in
CKIP-1. In the peptide competition assay, CKIP-1 bound to CP
better than CARMIL, suggesting that an alanine residue at this
position might enhance binding. To address this, we generated
a mutated construct with alanine substituted for proline in
CD2AP and tested its ability to bind to CP. Surprisingly, this
construct had ⬃50% lower binding compared with wild-type
CD2AP (data not shown). This result confirmed that the conserved proline in CD2AP is important for binding and demonstrates that the binding difference between CKIP-1 and CD2AP
is not due to the alanine residue. The higher affinity of CKIP-1,
however, does suggest that there is a level of complexity of the
binding that goes beyond the binding motif that we identified
here. It is interesting to note that the residues between Lys-495
and Pro-502 are mainly basic residues. These residues might
play important roles in modulating binding.
We searched the data base for other proteins containing this
motif but did not identify any others. Although it is possible
that these four proteins are the only molecules containing this
motif, it seems more likely that variants of this motif exist. Nevertheless, our peptide competition studies demonstrate that
this motif is used similarly by CD2AP, CKIP-1, and CARMIL to
bind to CP.
The COOH termini of both the ␣ and ␤ subunits of CP are
important for its capping activity (16), and they were also
important for CD2AP binding. The interaction of CARMIL
with CP, however, did not require either the ␣ or ␤ COOH
termini regions of CP for binding (20). Because the fragment of
CARMIL used was much larger than the portion of CD2AP
tested here, this suggests that CARMIL might interact with
other regions of CP in addition to the area that was defined
here. Mapping studies with CARMIL will be required to determine whether additional interacting sites exist.
Because the ␤ COOH-terminal region was involved in
CD2AP binding, and the ␤1 and ␤2 isoforms differ in this
region (35), we tested whether the CD2AP interaction with
CP was ␤ isoform-specific. The two isoforms of CP (␣1␤1,
␣1␤2) had similar binding affinities to CD2AP (data not
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shown). This suggests that CD2AP interacts with conserved
residues within the COOH-terminal regions of the ␤1 and ␤2
isoforms or that the specific sequence of the ␤ COOH terminus is not important.
Our data suggest that CD2AP can regulate actin dynamics by
partially inhibiting CP and/or by promoting uncapping of the
barbed end. Similar to CARMIL, we found that CD2AP does
not completely block the capping activity of CP (20). At saturating amounts of CD2AP, some capping activity of CP was still
retained. Although this may be secondary to the fact that we
tested only fragments of CD2AP rather than the full-length
protein, we are intrigued by the possibility that CD2AP binding
to CP may function to modulate and not completely inhibit its
activity. Because the concentration of CP and CD2AP in cells
(estimated in the M range) is far above the affinity of CP for the
barbed ends, the CP䡠CD2AP complex is likely to retain significant capping activity in vivo. With the growing number of identified CP-binding proteins, the potential for each to change the
binding affinity of CP in different ways may allow for a broader
diversity of actin filament structures.
This might not be the only way CD2AP regulates the actin
cytoskeleton. Similar to CARMIL, we found that CD2AP can
uncap barbed end filaments (18, 20). CD2AP joins CARMIL
as the only known proteins able to uncap barbed ends. Given
the high affinity of CD2AP for CP, it would be expected that
much of the CP would be bound to CD2AP in the cell. However, given the increasing number of identified CP-binding
proteins, it seems more likely that distinct pools of CP exist
bound to different CP-binding proteins. Because CD2AP
and its homolog Cin85 can form heterodimers mediated by
their coiled-coil domain3 and both can bind to CP, it is very
likely that they form a ternary complex in cells. It will be
interesting to determine how these complexes are regulated
in vivo, because CD2AP is associated with other actin regulatory proteins such as cortactin (12). The role of CD2AP in
actin regulation could be complex. We are interested to
determine what roles CD2AP plays in regulating other
modes of actin polymerization.
Recently, Mejillano et al. (36) have demonstrated that the
balance between filopodia and lamellopodia is dependent on
CP. When CP expression is inhibited using RNA interference, long unbranched actin filaments are favored over short
branched actin filaments. Thus, it is conceivable that
recruitment of CD2AP to the plasma membrane might
inhibit CP activity and thereby function to enhance filopodia
formation or decrease the density of branched filaments.
However, we were unable to confirm this hypothesis in cells.
Phalloidin analysis of CD2AP-deficient cells compared with
wild-type cells did not show any differences nor did motility
studies (data not shown). In addition, clustering of a COOHterminal fragment of CD2AP (containing the capping binding site) to the plasma membrane did not induce any local
filopodia. Overexpression of full-length CD2AP also had no
obvious effect on the actin cytoskeleton. Although the presence of Cin85 could be a confounding factor in our experi-

3

T. B. Huber and A. S. Shaw, unpublished data.
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ments, these results suggest that CD2AP-dependent changes
in the actin cytoskeleton cannot account for the podocyte
defect responsible for renal failure. We are, however, continuing to investigate whether the actin and adhesion molecule dynamics is affected by CD2AP.
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